Fusion Medical preparing for clinical study of flowable gel to stop heavy surgical bleeding.
This article was originally published in The Gray Sheet
Executive Summary
FUSION MEDICAL'S FLOWABLE GEL COLLAGEN SEALANT CLINICAL TRIALS for cardiovascular and general surgery are slated to commence during the second quarter, Philip Sawyer, president and CEO of Fusion Medical Technologies said at a March 25 New York Society of Security Analysts meeting in New York City. The collagen-based sealant can stop active bleeding in approximately one minute, the company claims.